SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

XFOR

X4 Pharmaceuticals Inc.
NASDAQHealth Care

Latest close: 2.59 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 8, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Oct 1, 2026Reported sale · Form 4DAVID KIRSKE, Chief Financial Officer · $33.7KOpen the filing ↗
  3. Oct 1, 2026Notice of sale · Form 144David Kirske · Officer · $33.7KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record75920 flagged findings
Reported transactions (Form 4)61since Aug 31, 2023 · and 2 other holdings
Corporate events (8-K)30since May 4, 2023

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-06capital return (buybacks/dividends)recentOpen filing ↗
    “…the amount of debt securities of such series whose holders must consent to an amendment, supplement or waiver; • reduce the rate of…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:30 on Apr 28, 2025) · 1:30 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 759)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 8, 268-K ↗Current report · A material agreement was terminated
  • Oct 7, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 4.6% · event on Sep 30, 26 · amendment
  • Oct 5, 26Form 4 ↗Insider transaction
  • Oct 1, 26Form 144 ↗Notice of proposed sale
  • Sep 21, 26SCHEDULE 13G ↗Passive stake · Venrock Healthcare Capital Partners III, L.P. · 5.6% · event on Sep 14, 26
  • Sep 9, 268-K ↗Current report · Other events
  • Sep 8, 268-K ↗Current report · Other events
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Perceptive Advisors LLC · 8.1% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Deep Track Capital, LP · 8.3% · event on Jun 30, 26 · amendment
  • Aug 13, 26Form 144 ↗Notice of proposed sale
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Aug 13, 26Form 144 ↗Notice of proposed sale
  • Aug 6, 2610-Q ↗Quarterly report
  • Jul 30, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.9% · event on Jun 30, 26
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jul 1, 26Form 3 ↗Insider transaction
  • Jul 1, 268-K ↗Current report · A senior executive left or was appointed
  • May 15, 26SCHEDULE 13G/A ↗Passive stake · Perceptive Advisors LLC · 7.3% · event on Mar 31, 26 · amendment
  • May 13, 268-K/A ↗Current report · A senior executive left or was appointed · amendment
  • May 13, 26Form 4 ↗Insider transaction
  • May 12, 268-K ↗Current report · A senior executive left or was appointed
  • May 12, 26CORRESP ↗Correspondence with the SEC
  • May 12, 26Form 144 ↗Notice of proposed sale

759 filings on record, the oldest from Sep 6, 17.

Listing the 25 most recent filings of the 759 on record.

8-Ks, explained

Stress5Structure53Governance27
  • Oct 8, 26StructureA material agreement was terminated+5 more in the same filing8-K 1.02 ↗
  • Governance3 senior executive changes2026show all 3hide
    • Jul 1, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • May 13, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K/A 5.02 ↗
    • May 12, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Oct 27, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Sep 17, 25StressRestructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
  • Aug 25, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Structure3 material agreements entered2025show all 3hide
    • Aug 13, 25StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
    • Aug 12, 25StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
    • Jun 23, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Feb 6, 25StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Jan 13, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Aug 16, 24StressListing notice (8-K 3.01)8-K 3.01 ↗
  • May 9, 24StructureEntered a material agreement+5 more in the same filing8-K 1.01 ↗
  • Nov 14, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Oct 18, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗

3 older filings not shown · The record reaches back to Jun 12, 18.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Feb 8, 19StressA debt obligation was accelerated8-K 2.04 ↗

The full record holds 5 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Coastlands Capital LP10.0%Aug 11, 25SCHEDULE 13D ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • Bain Capital Life Sciences Fund, L.P.10.0%Aug 11, 25SCHEDULE 13D ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • Growth Equity Opportunities 18 VGE, LLC6.2%Oct 27, 25SCHEDULE 13D/A ↗12 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Morgan Stanley10.2%Feb 28, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Empery Asset Management, LP10.0%Dec 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Deep Track Capital, LP8.3%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Perceptive Advisors LLC8.1%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BCLS II Equity Opportunities, LP7.4%Dec 31, 25SCHEDULE 13G/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
show 6 more holdershide
  • BlackRock, Inc.5.9%Jun 30, 26SCHEDULE 13G ↗
  • Trails Edge Capital Partners, LP5.8%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Venrock Healthcare Capital Partners III, L.P.5.6%Sep 14, 26SCHEDULE 13G ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
  • FMR LLC4.6%Sep 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • BVF PARTNERS L P/IL3.9%Dec 31, 25SCHEDULE 13G/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum.
  • Nantahala Capital Management, LLC2.8%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Oct 1, David Kirske filed notice of intent to sell up to $34K. That is about 0.01% of shares outstanding.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $34K on Oct 1, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+2 more recent notices

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 1, 26Sell$34KDAVID KIRSKEChief Financial Officer↗
  • Aug 12, 26Sell$211KAdam R CraigExecutive Chairman↗
  • Aug 12, 26Sell$109KJohn VolponePresident↗
  • Jun 30, 26Sell$36KDAVID KIRSKEChief Financial Officer↗
  • May 12, 26Sell$73KDAVID KIRSKEChief Financial Officer↗
  • Oct 23, 25Buy$250KAdam R CraigExecutive Chairman↗
  • May 16, 25Buy$3KMark BaldryChief Commercial Officer↗
  • Jan 24, 25Sell$5KChristophe Arbet-EngelsChief Medical Officer↗
  • Jan 24, 25Sell$10KMary DiBiaseChief Operating Officer↗
  • Jan 24, 25Sell$13KMark BaldryChief Commercial Officer↗
  • Jan 24, 25Sell$34KAdam S. MostafaChief Financial Officer↗
  • Jan 24, 25Sell$35KPaula RaganPresident and CEO↗

There are 7 more transactions in this stretch.

Stock compensation, tax and giftsshow the 21 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Aug 14, 25Compensationamount n/aDAVID KIRSKEChief Financial Officer↗
  • Aug 14, 25Compensationamount n/aAdam R CraigExecutive Chairman↗
  • Aug 14, 25Compensationamount n/aJohn VolponePresident↗
  • Jun 9, 25Compensationamount n/aMICHAEL S WYZGA↗
  • Jun 9, 25Compensationamount n/aDAVID W J MCGIRR↗
  • Jun 9, 25Compensationamount n/aKeith Woods↗
  • Jun 9, 25Compensationamount n/aGary Bridger↗
  • Jun 9, 25Compensationamount n/aCraecker Francoise de↗
  • Jun 9, 25Compensationamount n/aMurray Stewart↗
  • May 20, 25Compensationamount n/aNatasha Fay ThorenChief Legal Officer↗
  • May 16, 25Compensation$3KMark BaldryChief Commercial Officer↗
  • Feb 12, 25Compensationamount n/aMary DiBiaseChief Operating Officer↗
  • Feb 12, 25Compensationamount n/aMark BaldryChief Commercial Officer↗
  • Feb 12, 25Compensationamount n/aPaula RaganPresident and CEO↗
  • Feb 12, 25Compensationamount n/aAdam S. MostafaChief Financial Officer↗
  • Feb 12, 25Compensationamount n/aChristophe Arbet-EngelsChief Medical Officer↗
  • Jan 23, 25Compensationamount n/aChristophe Arbet-EngelsChief Medical Officer↗
  • Jan 23, 25Compensationamount n/aMary DiBiaseChief Operating Officer↗
  • Jan 23, 25Compensationamount n/aMark BaldryChief Commercial Officer↗
  • Jan 23, 25Compensationamount n/aAdam S. MostafaChief Financial Officer↗
  • Jan 23, 25Compensationamount n/aPaula RaganPresident and CEO↗

The full record holds 103 transactions and goes back to Feb 13, 23.

Its sector and its market

X4 Pharmaceuticals Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From X4 Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow X4 Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
759 documents on file, from Sep 6, 2017 to Oct 8, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.